Ceftazidime-Avibactam versus Meropenem-Vaborbactam for the Treatment of Bloodstream Infections and/or Pneumonia due to Carbapenem-resistant EnterobacteraLes# (CAMEL)

Abstract The CAMEL study is a retrospective, multicenter, observational cohort study of patients with carbapenemase positive Enterobacterales pneumonia or bloodstream infection treated with ceftazidime-avibactam or meropenem-vaborbactam. Enrolling sites will collect electronic medical record data to evaluate the clinical outcomes of adult patients. Data will be entered into a secure online database (REDCap). Sites may enter up to 20 patient cases in the ceftazidime-avibactam arm and 50 cases in the meropenem- vaborbactam arm. Available bacterial isolates from validated cases will be shipped to the Coordinating Center (University of Pittsburgh) for antibiotic susceptibility testing and identification of mechanisms of resistance via whole genome sequencing. For all isolates from the Institution which are tested by the University of Pittsburgh, results will be returned to the Institution.